Clinical Trial Update: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer [Phase 1]

View source ↗

Summary

This is a Phase 1 trial update for Bavarian Nordic's TAEK-VAC-HerBy Vaccine targeting brachyury and HER2-expressing cancers, including chordoma and HER2-positiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chordoma

Drugs mentioned

• TAEK-VAC-HerBy Vaccine (TAEK-VAC-HerBy)

Snippet

Sponsor: Bavarian Nordic | Conditions: Chordoma, HER2-positive Breast Cancer | Phase 1 | Status: COMPLETED